Mumbai, January 05, 2026: Eros Innovation has announced a collaboration between its AI-driven health platform Eros LifeScience and the Centre for Cancer Epidemiology (CCE), Tata Memorial Centre (TMC), Mumbai, to launch Gujarat CARES 2025, a large-scale preventive health initiative aimed at advancing early detection and population health research in India.
The multi-year longitudinal study will be powered by Eros GenAI, the ethical and sovereign AI foundation model developed by Eros Innovation. The initiative is designed to analyse genetic, lifestyle, environmental, behavioural, and digital health determinants to better understand the risks associated with cancer, diabetes and metabolic disorders, cardiovascular health, kidney and liver disease, women’s health, mental health, ageing, and longevity.
Data generated through the study will contribute to the Eros LifeScience AI Health Graph, supporting the development of AI-enabled early warning digital biomarkers, personalised preventive health scores, wellness and longevity pathways, and state- and national-level public health dashboards. The initiative is positioned as a step towards building an AI-powered public health prevention framework aligned with India’s healthcare priorities.
Manju Lulla, Chairperson, Eros LifeScience, said, “Every family deserves early warning, not late discovery. For decades, Eros has taken Indian stories and cinema to audiences across the world. With Eros LifeScience and Eros GenAI, we now want India to lead in something even more fundamental - keeping people healthier for longer.”
Dr. Rajesh Dixit, Director, Centre for Cancer Epidemiology, Tata Memorial Centre, stated, “Gujarat CARES 2025 represents a major step forward in population-scale preventive health research. We are pleased to partner with Eros LifeScience and Eros GenAI, who are emerging as leaders in the application of ethical, large-scale AI to preventive healthcare. Their advanced AI platforms add a powerful new dimension to long-term epidemiological research, enabling high-quality, actionable insights for early detection, risk stratification, and prevention strategies that can meaningfully shape public health policy in India.”
Dr. Pankaj Chaturvedi, Director, ACTREC, said, “Tata Memorial Centre, ACTREC, and the Centre for Cancer Epidemiology are happy to work with Eros LifeScience to enable the Gujarat CARES 2025 study. The study employs a longitudinal methodology to investigate genetic, lifestyle, and environmental risk factors, integrating scientific rigor with robust community engagement. As an expansion of the Indian Study of Healthy Ageing (ISHA), this research is being conducted by the Molecular Epidemiology and Population Genomics divisions of CCE across Barshi, Varanasi, and Goa. The objective is to generate high-quality evidence that will support early detection strategies, personalized risk assessment, and the formulation of informed national health policies.”
Dr. Shilpa Desai, CEO, Eros HealthScience and R&D, added, “Eros LifeScience is building one of the world’s most advanced AI-powered prevention engines. Gujarat CARES will generate real-world scientific evidence to detect risks early and save lives.”
Through Gujarat CARES 2025, Eros Innovation and Tata Memorial Centre aim to strengthen preventive healthcare research using ethical AI, with a focus on early detection, evidence-based policymaking, and scalable public health solutions for India and other emerging markets.
x
.jpg)
.jpg)
